Lantern Pharma Inc.
NASDAQ:LTRN
Overview | Financials
Company Name | Lantern Pharma Inc. |
Symbol | LTRN |
Currency | USD |
Price | 4.12 |
Market Cap | 44,432,964 |
Dividend Yield | 0% |
52-week-range | 2.79 - 11.99 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Panna Sharma PH.D. |
Website | https://www.lanternpharma.com |
An error occurred while fetching data.
About Lantern Pharma Inc.
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD